T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Tesla
TSLA
|
+$4.45B |
| 2 |
JPMorgan Chase
JPM
|
+$2.22B |
| 3 |
Atlassian
TEAM
|
+$2.08B |
| 4 |
NVIDIA
NVDA
|
+$1.81B |
| 5 |
Apple
AAPL
|
+$1.67B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class C
GOOG
|
+$3.24B |
| 2 |
Meta Platforms (Facebook)
META
|
+$3.08B |
| 3 |
Microsoft
MSFT
|
+$2.68B |
| 4 |
Wells Fargo
WFC
|
+$1.93B |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$1.86B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.79% |
| 2 | Healthcare | 17.19% |
| 3 | Consumer Discretionary | 15.16% |
| 4 | Financials | 10.74% |
| 5 | Communication Services | 10.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2801
LifeVantage
LFVN
$81.1M
| $123K | ﹤0.01% |
25,900
| – | – |
|
|
SFR
2802
DELISTED
Appreciate Holdings, Inc. Class A Common Stock
SFR
| $122K | ﹤0.01% |
12,361
| – | – |
|
2803
Kopin
KOPN
$892M
| $121K | ﹤0.01% |
48,000
+2,300
| +5% | +$6.62K |
|
|
VVNT
2804
DELISTED
Vivint Smart Home, Inc. Class A Common Stock
VVNT
| $121K | ﹤0.01% |
17,828
+5,130
| +40% | +$36.6K |
|
2805
Alto Ingredients
ALTO
$329M
| $119K | ﹤0.01% |
17,494
+1,853
| +12% | +$10.4K |
|
2806
Ovid Therapeutics
OVID
$513M
| $119K | ﹤0.01% |
37,961
| – | – |
|
|
IVAC
2807
DELISTED
Intevac Inc
IVAC
| $119K | ﹤0.01% |
22,200
| – | – |
|
2808
Hippo Holdings
HIPO
$875M
| $117K | ﹤0.01% |
+2,356
| New | +$122K |
|
2809
The ONE Group
STKS
$56.5M
| $117K | ﹤0.01% |
+11,153
| New | +$131K |
|
2810
Cullinan Oncology
CGEM
$1.29B
| $116K | ﹤0.01% |
11,127
+500
| +5% | +$6.75K |
|
2811
Quad
QUAD
$502M
| $116K | ﹤0.01% |
16,700
| – | – |
|
2812
MediciNova
MNOV
$64.5M
| $115K | ﹤0.01% |
43,100
+11,600
| +37% | +$28.4K |
|
2813
MiMedx Group
MDXG
$609M
| $114K | ﹤0.01% |
24,235
+2,482
| +11% | +$12.1K |
|
2814
SELLAS Life Sciences
SLS
$2.52B
| $114K | ﹤0.01% |
17,100
| – | – |
|
2815
SFL Corp
SFL
$1.62B
| $113K | ﹤0.01% |
+11,074
| New | +$102K |
|
|
SUNW
2816
DELISTED
Sunworks, Inc.
SUNW
| $112K | ﹤0.01% |
44,600
| – | – |
|
|
MTEM
2817
DELISTED
Molecular Templates, Inc.
MTEM
| $111K | ﹤0.01% |
2,144
+80
| +4% | +$3.53K |
|
2818
VistaGen Therapeutics
VTGN
$11.6M
| $110K | ﹤0.01% |
2,946
+134
| +5% | +$5.84K |
|
|
AMPE
2819
DELISTED
Ampio Pharmaceuticals Inc.
AMPE
| $107K | ﹤0.01% |
757
+171
| +29% | +$25K |
|
2820
ClearPoint Neuro
CLPT
$464M
| $106K | ﹤0.01% |
+10,192
| New | +$92.8K |
|
2821
Citizens
CIA
$201M
| $105K | ﹤0.01% |
24,785
+1,100
| +5% | +$4.97K |
|
2822
PEDEVCO
PED
$161M
| $105K | ﹤0.01% |
3,905
| – | – |
|
|
MRNS
2823
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $105K | ﹤0.01% |
+11,183
| New | +$111K |
|
|
AERI
2824
DELISTED
Aerie Pharmaceuticals
AERI
| $105K | ﹤0.01% |
11,512
-1,892
| -14% | -$14.6K |
|
|
DCH
2825
Dauch Corp
DCH
$1.58B
| $104K | ﹤0.01% |
+13,412
| New | +$114K |
|
Similar funds
T. Rowe Price Associates's Q1 2022 Portfolio in Review
As of Q1 2022, T. Rowe Price Associates held 3,085 positions worth $992B, down 11% from $1.11T the previous quarter. Its ten largest holdings account for 28% of the portfolio.
T. Rowe Price Associates's Q1 2022 filing shows 108 new, 1,637 increased, 1,059 reduced and 107 closed positions. Its largest new stake was Nutrien: 6,143,560 shares worth $639M. The largest sale was Alphabet (Google) Class C, an estimated $3.24B.
By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q1 2022 buy was Nutrien: 6,143,560 shares worth $639M.
- T. Rowe Price Associates added most to Tesla in Q1 2022, an estimated $4.45B increase.
- T. Rowe Price Associates's biggest Q1 2022 reduction was Alphabet (Google) Class C, cutting an estimated $3.24B.
- T. Rowe Price Associates fully exited Xilinx Inc in Q1 2022, selling an estimated $481M.
- T. Rowe Price Associates's ten largest holdings make up 28% of its $992B portfolio in Q1 2022.
- T. Rowe Price Associates opened 108 new positions and closed 107 in Q1 2022.
- T. Rowe Price Associates's portfolio value fell 11% quarter-over-quarter to $992B.
Based on T. Rowe Price Associates's 13F filing for Q1 2022, filed 16 May 2022.